Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth

Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.